Objective: The objective of this article was to develop and validate a scale that assesses the readiness of gynecologic oncology patients to engage in advance care planning. Methods: The Advance Care Planning Readiness Scale (ACPRS) was validated across 3 independent samples of gynecologic oncology patients. In step I, patients underwent cognitive interviewing to determine if the scale items were comprehensible and applicable to patients. Based on this, modifications to the scale (addition, removal, and merger of items) were completed. In step II, the revised scale was administered to a new sample of patients to assess scale reliability and validity. An exploratory factor analysis determined if the scale loaded onto unique factors. In step III, the revised scale was administered to a third sample of patients, and a confirmatory factor analysis was conducted to test the factor structure proposed in step II. Associations between ACPRS score and completion of advance directives were evaluated. Results: Based on patients' responses, the original ACPRS used in step I was modified to the ACPRS used in step II. The final 8-item ACPRS is a valid, reliable (Cronbach > = 0.81) scale and has 2 primary factors. Women with medical power of attorney documents and living wills had higher ACPRS total scores than those who did not have these advance directives (P = 0.0030). Women with do-not-resuscitate (DNR) orders had higher ACPRS total scores than women without DNRs (P = 0.0176). Conclusions: The ACPRS is a valid and reliable 8-item scale that assesses the readiness of gynecologic oncology patients to discuss advance care planning issues.
C ommunication regarding advance care planning is an important, but often neglected, component of caring for patients with cancer. 1 Early advance care planning allows the patient to transition from active treatment of cancer to the management of the physical, spiritual, and emotional needs of the terminally ill patient. Advance care planning is defined as the activities that the patient participates in with her health care team and her family to determine her end-of-life care (EOLC) goals. 2, 3 This planning includes the creation of advance directives such as a medical power of attorney, living will, and do not resuscitate (DNR) order and discussions between the patient, the health care team, and the patient's family regarding the patient's overall EOLC goals relating to the management of her disease and the transition to the end of life. 2, 3 Research demonstrates that early EOLC discussions can improve the likelihood that patients' final wishes are honored at the end of life and may result in decreased distress for the patient. 4 Early EOLC discussions are associated with a decreased number of invasive procedures and treatments at the end of life, resulting in increased quality of life and decreased health care costs. 5Y7 Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend that advance care planning discussions occur early in a cancer patient's disease course. 8, 9 Patients experience differing levels of comfort discussing EOLC issues with their providers, making this an area that could benefit from interventions targeted at improving patient-provider communication. Specifically, the ability to objectively assess a patient's interest in discussing EOLC issues could allow for better patient-provider communication by identifying those patients who are interested in and open to talking about their EOLC preferences. Unfortunately, no standardized scale currently exists to assist providers in assessing gynecologic oncology patients' willingness and readiness to discuss these topics. The goal of this study was to develop and validate a scale that assesses the readiness of gynecologic oncology patients to engage in EOLC discussions, which are a critical part of advance care planning.
MATERIALS AND METHODS
The Advance Care Planning Readiness Scale (ACPRS) was validated across 3 independent samples (steps IYIII) of gynecologic oncology patients at The University of Texas MD Anderson Cancer Center. Patients were eligible to participate in the institutional review boardYapproved study if they (1) had a gynecologic malignancy, (2) were currently receiving treatment or in active surveillance at our institution, (3) had an Eastern Cooperative Oncology Group performance score of 2 or less, (4) were able to speak, read, and understand English, and (5) were able to provide written informed consent. Patients meeting the eligibility criteria were identified using clinic templates and the electronic medical record. Eligible patients were then recruited from the gynecology clinic at their followup appointment. Patients were intentionally recruited to evenly represent women receiving treatment and those who were not to allow equal representation of patients undergoing treatment and those in surveillance. Participation was voluntary and without compensation. The anonymity of the participants was maintained throughout the study, and the patient's attending physician (treating provider) had no knowledge of patient survey responses. All results were anonymized before statistical analyses. The three steps necessary for validation of a scale were conducted in the present study.
Step I is the formation and development of the scale.
Step II tests the reliability and validity of the scale and examines how many factors (or subcategories) the scale has.
Step III confirms that the number of factors identified in Step II is correct. The methodology of each step in the scale validation is described below.
Step I Methodology
The initial ACPRS was a 13-item scale developed by generating a larger pool of items based on issues covered in the EOLC literature, physicians' experiences with patients, and items pilot-tested by the investigators. Previous unpublished work by 1 of the authors of this protocol (A.J.B.) pretested an EOLC readiness scale composed of 2 factors: willingness to discuss EOLC and acceptance of EOLC among 140 patients seen in a gynecologic oncology clinic in Baltimore, Md. This evaluation demonstrated good internal reliability within those 2 factors with a Cronbach > value of 0.77 for the willingness to discuss EOLC factor and Cronbach > value of 0.71 for the acceptance of EOLC factor. Scale validation was not done during this study but it demonstrated the potential internal validity of this type of construct. Additional items were added to the pilot scale after discussion of important topics relating to EOLC with an expert panel of gynecologic oncologists, communication specialists, and survey development experts. The final pool of items included in the current study were reviewed and modified by this expert panel. The 13-item ACPRS had a 7-point Likert-type response scale (1 = strongly disagree, 7 = strongly agree). Higher scores on the ACPRS indicate increased overall readiness to discuss and make EOLC decisions.
A total of 25 patients were enrolled in step I. Patients completed a background questionnaire regarding age, race/ ethnicity, marital status, education, religion, and occupation. Details regarding the patient's cancer, current treatment, and presence of DNR and advance directives were obtained from the medical record. Participants completed the self-administered 13-item ACPRS. After scale completion, trained research personnel conducted a cognitive interview regarding the 13-item ACPRS using methods outlined by Rubin and Rubin. 10 All interviews were recorded via a digital recorder and audited by the study staff who completed the cognitive interviews to collect data for the thematic analysis.
Step II Methodology
The modified 11-item scale created from step I (see results) was tested for reliability and validity in step II with an independent sample of 110 patients. Patients were asked to complete the step I background questionnaire, the modified 11-item ACPRS, and 3 additional measures to assess convergent and divergent validity (detailed hereinafter). Details regarding the patient's cancer were obtained from the medical record as in step I. Patients received an addressed, stamped envelope and were asked to take the ACPRS home and complete it again 1 week after their initial participation in the study to assess test-retest reliability.
Questionnaires Used in Step II
Peace, Equanimity, and Acceptance in the Cancer Experience Questionnaire
The Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE) questionnaire is a validated 12-item measure composed of 2 subscales, a 7-item Struggle with Illness subscale and a 5-item Peaceful Acceptance subscale.
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All items are measured using a 4-point Likert-type scale (1 = not at all, 4 = to a large extent). Higher scores indicate increased struggle with illness or peaceful acceptance. The Struggle with Illness subscale has a significant positive association with advance care planning activities such as living will formation or health care proxy designation. 11 The Peaceful Acceptance subscale has a significant inverse relationship with feeding tube usage at the end of life. 11 This scale was used to assess the convergent validity of the ACPRS. We hypothesized that the ACPRS would be positively associated with the Struggle with Illness and the Peaceful Acceptance subscales.
Templers' Death Anxiety Scale
The Templers' Death Anxiety Scale (DAS) is a validated scale composed of 15 true/false questions that assess an individual's level of anxiety surrounding death. 12 A higher score indicates increased death anxiety. This scale was used to assess the convergent validity of the ACPRS. We hypothesized that the ACPRS would be negatively associated with the DAS.
Shortened Marlowe-Crowne Social Disability Scale
The Shortened Marlowe-Crowne Social Desirability Scale (MCSDS) is a validated scale composed of 10 true/false questions that assess an individual's endorsement of socially desirable characteristics. 13, 14 A higher score indicates increased concern for being viewed as having socially desirable characteristics. This scale was used to assess the divergent validity of the ACPRS because the two scales were not expected to be associated.
Step III Methodology A confirmatory factor analysis (CFA) of the ACPRS was conducted with an independent sample of 110 patients to verify the results obtained in step II. Patients completed the step I background questionnaire and the 11-item ACPRS. Details regarding the patient's cancer were obtained from the medical record as in step I.
Step I Statistical Analyses Thematic analysis was used to code the qualitative data from the cognitive interviews to determine which items should be modified (to enhance understanding), cut (because of irrelevance to patients), or added (because of importance to patients) to the 13-item ACPRS before starting step II.
Step II Statistical Analyses
Cronbach > was calculated to assess internal reliability. An exploratory factor analysis was conducted to determine the factors/constructs that the ACPRS measured. Convergent validity was assessed by correlating ACPRS scores with PEACE Struggle, PEACE Acceptance, and DAS scores. A Bonferroni correction was applied to control for type I errors when assessing convergent validity; therefore, a cutoff of P value less than 0.0167 for correlations was used to assess convergence to achieve a familywise type I error of 0.05. Divergent validity was assessed by correlating the ACPRS with the MCSDS and testing H A : Q = 0. If the 90% Step 1
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A CFA was conducted to verify that the results obtained from step II and the exploratory factor analysis performed were reproducible (Fig. 1) . Model fit was evaluated by examining the following: (1) the root mean square error of approximation (RMSEA), 15 (2) the Tucker Lewis Index (TLI), also known as the Nonnormed Fit Index, (3) the Comparative Fit Index (CFI), 16 and (4) the standardized root mean square residual (SRMR). 17 
RESULTS

Step I Results
Patients from this sample were predominately white (84%) and had endometrial (44%) or ovarian (40%) cancer (Table 1) . Participation rate was 93% (25/27). Most found the ACPRS clear and straightforward. A recurring theme suggested by patients was to add qualifiers to the questions, such as specifying what ''medical treatment'' meant (eg, ''CPR'') and using ''if my cancer were terminal/untreatable'' to specify when EOLC discussions or planning would occur. Using the information collected during the cognitive interviewing in step I, the original 13-item ACPRS used in step I was modified to form the 11-item ACPRS used in step II (Table 1 , Supplemental Digital Content 1, http://links.lww.com/IGC/A455).
Step II Results
Patients from this sample were predominately white (76.36%) and had ovarian (46%) or endometrial (35%) cancer (Table 1) . Participation rate was 74% (110/149).
Reliability
The initial assessment of reliability indicated that items 1, 3, and 10 (from the modified 11-item scale administered in step II) had low correlations with the total score (G0.3). Accordingly, these items were removed from the ACPRS, resulting in the final 8-item scale (Table 2) . (Table 4) .
Exploratory Factor Analysis
Principal components factoring was used to extract factors from the data. An examination of the scree plot indicated that 2 factors would be sufficient to explain 70% of the variability in the data, suggesting that the 8-item ACPRS represents a 2-factor scale (Table 5 ). An examination of the rotated factors indicated that items 2, 4, 5, 6, and 7 of the 8-item ACPRS loaded heavily onto factor 1 (Willingness to Discuss EOLC), and items 8, 9, and 11 loaded heavily onto factor 2 (Acceptance of EOLC). With the exception of item 11, uniqueness ranged from 0.19 to 0.32. Accordingly, each item other than item 11 was assumed to measure a unique component of the 2 factors.
Validity
The 8-item ACPRS was positively correlated with the PEACE Acceptance subscale (r = 0.35, P = 0.0005) and negatively correlated with the PEACE Struggle subscale (r = j0.28, P = 0.0055), providing evidence for convergent validity. It was not significantly correlated with the DAS. It was adequately divergent from the MCSDS (r = j0.05; 90% CI, j0.23Y0.12). Validation of the scale held when examining only those with active disease, but failed to find convergent validity when examining only those in surveillance (Table 4 , Supplemental Digital Content 4, http://links.lww. com/IGC/A455).
The ACPRS Associations with Demographic, Medical, and EOLC Outcomes Table 4 provides the association between the ACPRS score with demographic, medical, and EOLC outcomes. Women with a living will or medical power of attorney had higher ACPRS total, willingness, and acceptance scores than those who did not have advance directives (P = 0.0030, P = 0.0328, and P = 0.0031, respectively). In addition, women with DNRs had higher ACPRS acceptance and total scores than women without DNRs (P = 0.0322 and P = 0.0176, respectively). Cancer site or stage did not affect patients' ACPRS score.
Step III Results
Patients from this sample were predominately white (75%) and had ovarian cancer (54%) ( Table 1) . Participation rate was 84% (110/131).
Confirmatory Factor Analysis
An initial CFA indicated a modestly fitting model (RMSEA, 40.18; Pr[RMSEA e 0.05] G 0.001; CFI, 0.89; TLI, 0.84; SRMR, 0.07). 15, 16, 18 However, modification indices indicated that the error term for item 3 (item 5 on the original scale) was correlated with the error term for item 4 (modification index = 36.12) and subsequently item 5 (modification index = 14.87) (items 6 and 7 on the original scale). Because correlation between e 3 with both e 4 
CONCLUSIONS
The results of our study indicate that the ACPRS is a valid and reliable scale composed of 2 factors: (1) Willingness to Discuss EOLC and (2) Acceptance of EOLC. The scale was associated with patients' advance care planning documentation, with those with a higher total ACPRS score being more likely to have advance care documentation such as a medical power of attorney, a living will, or a DNR order. This suggests that the ACPRS may be useful in assessing a patient's interest in engaging in advance care planning conversations with her medical provider and may indicate to providers when patients are ready to initiate advance care planning documentation.
Convergent validity of the ACPRS was assessed by examining the association between the ACPRS and the PEACE scale as well as the DAS. We found a positive correlation with the PEACE Acceptance subscale but a negative correlation with the PEACE Struggle subscale. The negative correlation observed between the ACPRS and the PEACE Struggle subscale inherently makes sense, but the directionality is not as originally hypothesized. We had originally thought the two scales would be positively correlated based on findings described in the Materials and Methods section. The negative correlation noted between the ACPRS and the PEACE Struggle subscale may be because of attributes of the PEACE scale that were not taken into consideration before the data collection for our study. For example, the original PEACE study consisted only of patients with terminal disease, but 47% of our subjects were free of their cancer and in surveillance. 11 In addition, of those being treated for cancer, terminal disease was not an eligibility requirement for our study. It is possible that because patients in the PEACE study were terminally ill, they were more likely to have addressed EOLC issues when compared with our sample. In addition, 50% of the patients in the PEACE study were men, but our study only consisted of women. Men may struggle with their illness differently than women and may be more likely to implement advance care planning documentation, thus leading to a positive correlation between struggle with illness and advance care planning documents.
The ACPRS had a trend toward a negative correlation with the DAS, but the correlation was not significant as originally hypothesized. This could be because the analysis was not properly powered to assess whether or not the relationship was statistically significant because many patients choose not to complete the DAS. Specifically, many patients chose not to complete this scale because they felt it was too ''morbid'' because it asked pointed questions regarding how the patient felt about death. Divergent validity of the ACPRS was assessed by examining the relationship between the ACPRS and the MCSDS. The ACPRS was not significantly correlated with the MCSDS, confirming the divergent validity of the scale. Reliability testing of the ACPRS indicates that the total ACPRS and its two subscales (Willingness to Discuss EOLC and Acceptance of EOLC) are internally consistent. Moreover, the test-retest reliability indicates that this measure is reliable over time.
The strengths of our study include that it adhered to stringent psychometric scale development methodology and was developed in conjunction with input from physicians, psychometricians, and patients. The patients in our study were at varying points in their cancer management, which allows for the scale to be generalized to a broader population that includes patients in all stages of cancer management.
Our study was limited by the fact that it was restricted to female participants with a gynecologic malignancy. In addition, our patients were American and most were white. The fact that our study population consisted of Americans and primarily white women limits the ability to generalize the ACPRS to other populations. Accordingly, the scale in its current state is not reliable to use among patients who are not women, do not speak English, and are not American (ie, other cultures outside of the one that the ACPRS was validated in). This is a limitation present in all scale validation studies. Future developments of the scale should include male participants, other cultures, and other cancer types to assess whether the scale is valid to administer to other populations outside of American women with a gynecologic cancer. In addition, future work should examine what potential ''cutoff '' points for this scale would indicate that a patient is ready and willing to begin discussing advance care planning and EOLC. This could help guide clinicians regarding when to have these difficult conversations.
Early discussion regarding advance care planning goals for cancer patients is a quality care indicator that is likely to be more scrutinized in the future. Providers must develop ways to improve communication with patients regarding these topics. Tools that assess a patient's level of comfort and interest in these discussions may encourage the conversations to occur in a timely and efficient manner. Although EOLC conversations are challenging, it is imperative that providers encourage patients to engage in these difficult conversations before progressing to an advanced state of illness that renders them unable to make decisions for themselves. 17 The ACPRS is an 8-item scale that is valid and reliable. The scale provides a foundation for a tool that may be used to assess a gynecologic oncology patient's readiness to discuss EOLC topics and their acceptance of the need of EOLC support. We plan to conduct further evaluation of the ACPRS scale in other gynecologic oncology patient populations to identify the ACPRS score that constitutes patient readiness to discuss EOLC, to evaluate how often the scale should be administered, and to evaluate the best time to administer the scale to patients.
